- Ocean Rig UDW Inc. ORIG shares tumbled 54.4 percent to $0.985. Ocean Rig reported Q2 EPS $1.83 versus estimates of $0.72. Sales were $452.6 million versus estimates of $376.45 million. During the call, Chairman and CEO George Economou assured the company will focus on de-leveraging and maintaining liquidity, amidst “extremely negative” market conditions.
- Concordia International Corp CXRX shares dipped 26.3 percent to $12.06 as the company announced second quarter earnings that missed the estimates. Aside from that, the company slashed its forecast for the full year and suspended dividend.
- Xtera Communications Inc XCOM declined 21.3 percent to $0.890. Xtera Communications reported a Q3 loss of $1.35 per share on revenue of $5.3 million.
- Superior Drilling Products, Inc. SDPI shares fell 14.9 percent to $1.20. Superior Drilling Products reported a Q2 loss of $0.18 per share, on revenue of $1.114 billion.
- Aethlon Medical, Inc. AEMD shares dropped 12.9 percent to $6.59. Aethlon Medical reported a Q1 loss of $0.28 per share, versus a year-ago loss of $0.18 per share.
- Ruby Tuesday, Inc. RT shares declined 12.7 percent to $3.26 as the company posted weaker-than-expected earnings for its fourth quarter and announced plans to close around 95 underperforming restaurants.
- Crossroads Capital Inc XRDC fell 11.8 percent to $2.06 as the company reported the filing of its quarterly report on Form 10-Q.
- Voxeljet AG (ADR) VJET shares dropped 10.8 percent to $4.42. voxeljet reported a Q2 loss of EUR 0.46 per share on sales of kEUR 6,296. The company also lowered its full year 2016 revenue outlook.
- Applied DNA Sciences Inc APDN shares fell 9.7 percent to $2.77. Applied DNA Sciences reported a Q3 loss of $0.14 per share on revenue of $653,000.
- Payment Data Systems, Inc. PYDS declined 9.4 percent to $1.54. Payment Data Systems reported a Q2 loss of $0.05 per share on revenue of $2.9 million.
- Pernix Therapeutics Holdings Inc PTX fell 8 percent to $0.700. Pernix Therapeutics reported a Q2 loss of $0.47 per share on revenue of $36.746 million. Brean Capital downgraded Pernix Therapeutics from Buy to Hold.
- Amedica Corporation AMDA shares dropped 8 percent to $0.690. Amedica reported a Q2 loss of $0.40 per share on revenue of $4.02 million.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
